Beruflich Dokumente
Kultur Dokumente
Report
March 2015
Month Growth %
IPM overview
25
25
20
2015
15
2014
10
2013
5
0
20
15
10
5
0
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
+13%
MAT
90,346
Month
76,482
80,566
67,709
73,096
Growth
SPLY
66,054
2012
2013
6,414
2014
Nov
+16%
+12%
5,861
Oct
5,446
Sep
7,464
2015
61,394
55,577
4,551
2012
4,884
2013
5,395
2014
6,281
2015
IPM was valued at Rs. 90,346 crs and the retail sector was valued at Rs. 76,482 crs as of MAT Mar15 with CAGR growth of 11%
during the period 2012-15
Anti-infectives, Cardiac and Gastro Intestinal remains the leading therapeutic categories accounting for 36% of IPM
Indian companies continue to drive growth in the market with Sun catapulted to the top of the league, after its merger deal with
Ranbaxy fructified, as forecasted by IMS Health in Jan 15
Acute therapies dominates the market constituting 70% of IPM
1
Dec
381
Rank #41 - 60
488
494
249
15
18
14
18
14
% MS
12
21
19,244
13
11
9,976
4,762
5,901
6,029
3,087
% Gwth
43
38,851
21
11
830
Rank #31 - 40
22
1,623
Rank #11 - 20
% Gwth
43
3,193
Rank #1 - 10
Rank #21 - 30
% MS
11
12
18
12
Lupin moved up among the top 10 companies as a result of the merger of Ranbaxy with Sun; the market share of
the top 10 companies increased from 40% of IPM in Feb 15 to 43% in Mar 15 on MAT and month basis
The top 150 companies continue to account for 97% of IPM on MAT and month basis
Source: IMS Health TSA, Mar 15
Month
Cipla
470
269
Zydus Cadila
261
GlaxoSmithKline
254
Alkem
250
Macleods Pharma
248
19
226
Lupin Limited
214
24
7
10
19
26
11
17
Value
(Rs. Crs)
Sun
Cipla
MAT
Zydus Cadila
3,171
Alkem
3,113
GlaxoSmithKline
3,088
Macleods Pharma
2,933
Pfizer
2,745
Lupin Limited
220
218
3.4
Zydus Cadila
Macleods Pharma
217
3.3
GlaxoSmithKline
204
3.0
Lupin Limited
181
Intas Pharma
179
8.3
6.4
20
3
19
11
5
2,581
5.3
3.5
23
9
15
18
11
2.9
32
% Gwth
Alkem
2,717
Zydus Cadila
2,667
% MS
8.4
6.5
16
3,777
3.5
2.8
11
6,398
3.5
3.5
3.3
18
4,974
4.9
20
12
3.7
3.6
3.5
3.4
Macleods Pharma
2,556
3.3
GlaxoSmithKline
2,523
3.0
Pfizer
2,218
2,173
3.5
27
2,825
Lupin Limited
3.5
Mankind
2.9
3.8
21
Sun
Abbott
4.8
24
Value
(Rs. Crs)
Cipla
8.3
6.4
240
3.4
4,760
Mankind
Alkem
10
7,538
3,181
3.5
% MS
12
401
3.6
% MS
11
302
Mankind
2.9
% Gwth
5,742
Cipla
5.1
% Gwth
524
Abbott
6.3
TSA
Pfizer
Sun
8.3
12
382
Mankind
Abbott
11
618
Abbott
Value
(Rs. Crs)
% MS
% Gwth
SSA
Value
(Rs. Crs)
25
3.3
3.3
2.9
16
2.8
TSA: Macleods registered significant growth greater than 20% both on MAT and month basis.
SSA: Intas registered double the growth % of IPM during the month while Macleods and Mankind registered
significant growth greater than 20% both on MAT and month basis
Source: IMS Health TSA & SSA, Mar 15
3
Month
Intas Pharma
182
Aristo Pharma
176
Dr Reddys Labs
175
Emcure
169
Sanofi
USV
Glenmark Pharma
28
8
16
122
Torrent Pharma
2,170
11
Emcure
2,126
12
2,061
Dr Reddys Labs
Glenmark Pharma
USV
15
13
1,949
1,746
1,517
Alembic
1,494
Dr Reddys Labs
146
Emcure
144
% MS
2.6
14
135
128
Sanofi
123
Alembic
113
Micro Labs
104
1,902
Emcure
2.0
2.5
30
2.3
2.3
15
2.2
19
2.0
2.0
1.7
% MS
21
1,577
1,551
Alembic
1,354
1.7
Micro Labs
1,284
2.4
13
2.3
17
10
11
15
9
2.2
2.1
19
1,544
1.7
2.7
2.5
16
1,777
USV
1.8
12
1,651
Glenmark Pharma
Sanofi
2.6
28
2,037
1,796
Dr Reddys Labs
25
% Gwth
Aristo Pharma
2.3
2.8
15
Torrent Pharma
2.2
24
Value
(Rs. Crs)
Intas Pharma
% MS
10
2.4
1.9
USV
Glenmark Pharma
2.4
2.2
19
1,781
Micro Labs
2.4
2.3
21
2,381
2,019
156
1.6
% Gwth
Sanofi
160
Aristo Pharma
1.7
12
Aristo Pharma
Torrent Pharma
TSA
Micro Labs
2.4
2.0
24
177
2.4
2.0
20
% Gwth
Pfizer
2.2
14
147
Value
(Rs. Crs)
MAT
28
167
125
2.8
24
149
Alembic
Intas Pharma
33
209
Torrent Pharma
Value
(Rs. Crs)
% MS
SSA
Value
(Rs. Crs)
2.0
2.0
1.8
1.7
TSA The majority of companies in this bucket posted significant growth greater 20% than during the month
SSA Similarly, Dr. Reddys, Aristo, Torrent and Alembic posted strong retail growth greater than 20% during the
month
Source: IMS Health TSA & SSA, Mar 15
4
Month
Wockhardt Ltd
Ipca Labs
109
106
FDC
Unichem
79
MSD Pharma
78
6
15
70
Merck Limited
61
Franco Indian
61
Indoco
55
20
Ipca Labs
1,303
1,284
FDC
16
1.3
12
72
1.1
1.0
60
0.8
Franco Indian
57
11
0.9
0.8
Merck Limited
54
11
0.9
1.5
20
14
Indoco
1,164
Ipca Labs
1,139
1.4
Wockhardt Ltd
1,101
1.2
FDC
1.1
Unichem
959
1.1
0.8
% Gwth
Novartis Intl.
0.9
21
49
1.4
1,060
0.9
25
Value
(Rs. Crs)
1,006
15
1.5
1.5
58
% MS
850
35
6
MSD Pharma
FDC
MSD Pharma
1.6
Cadila Pharma
Unichem
Cadila Pharma
27
84
Unichem
0.7
% Gwth
Wockhardt Ltd
96
93
0.9
12
1,336
Ipca Labs
Novartis Intl.
1.0
28
Novartis Intl.
1.5
1.1
% MS
99
1.4
1.2
11
% Gwth
Wockhardt Ltd
TSA
Cadila Pharma
1.6
32
91
Value
(Rs. Crs)
MAT
37
121
Novartis Intl.
Value
(Rs. Crs)
% MS
SSA
Value
(Rs. Crs)
982
MSD Pharma
757
724
1.5
22
1.5
10
1.4
1.3
913
Cadila Pharma
% MS
1.2
1.0
15
1.0
Merck Limited
777
0.9
Franco Indian
689
10
0.9
Franco Indian
733
10
0.8
Merck Limited
686
10
0.9
Indoco
668
0.7
Indoco
11
12
604
0.8
TSA Wockhardt and Ipca registered double the IPM growth during the month
SSA Wockhardt, Ipca, Indoco and Cadila registered significant growth of 20% during the month
Source: IMS Health TSA & SSA, Mar 15
Highlights
TSA
SSA
NLEM/Non-NLEM
Value
SPLY
Feb '15
Mar '15
Rs. (crs)
Value Growth
(%)
Rs. (crs)
Rs. (crs)
989.1
1091.9
10.4
1119.2
1091.9
-2.4
Non-NLEM
5424.5
6371.7
17.5
6439.7
6371.7
-1.1
IPM
6413.6
7463.6
16.4
7558.8
7463.6
-1.3
NLEM
Mar '14
Mar '15
Rs. (crs)
Previous month
Value Growth (%)
SPLY
Volume
Mar '14
Previous month
Mar '15
Feb '15
Units (000)
Units (000)
Volume Growth
(% )
Mar '15
Units (000)
Units (000)
Volume Growth
(%)
380800
399972
5.0
406526
399972
-1.6
Non-NLEM
1184052
1298946
9.7
1322253
1298946
-1.8
IPM
1564851
1698918
8.6
1728779
1698918
-1.7
NLEM
NLEM impacted drugs constituted 15% of IPM in value terms with a growth of 10.4% as of MAT Mar 15 over same
period last year (SPLY)
The share of the non-NLEM drugs was 76% of IPM in volume terms for the month of Mar15
Source: IMS Health TSA, Mar 15
Month Growth
25
20
Indian
IPM
15
MNC
10
5
0
Apr 14
May 14
Jun 14
Jul 14
Aug 14
Sep 14
Oct 14
Nov 14
Dec 14
Jan 15
Feb 15
Mar 15
8,000
IPM
Value
7,000
6,000
Indian
5,000
4,000
3,000
2,000
MNC
1,000
0
Apr 14
May 14
Jun 14
Jul 14
Aug 14
Sep 14
Oct 14
Nov 14
Dec 14
Jan 15
Feb 15
Mar 15
Indian companies continue to capture the larger share of IPM at 74% during the month with a significant growth of
18.6% over Mar14
MNCs registered a growth of 10.4% as against the IPM growth of 16.4% during the month
Source: IMS Health TSA, Mar 15
Acute/Chronic trends
Growth (%)
25
IPM
Acute
Chronic
20
15
10
5
Top 5 TC 4s
Apr 14
May 14
Aug 14
Sep 14
20.40
Oct 14
Nov 14
Dec 14
17.63
Jan 15
-5.05
Feb 15
Mar 15
23.03
155
Jul 14
30.37
Growth (%)
Value (Rs.
Crs)
Jun 14
16
Wockhardt Ltd
Franco Indian
108
Glim+Metformin
Glenmark Pharma
118
MSD Pharma
27
USV
Novartis Intl.
26
Sun
Lupin Limited
USV
19
23
88
87
Food Supplements
Apex
15
GlaxoSmithKline
17
11
Abbott
14
Mankind
14
10
Nutricia Internat
13
Alkem
14
Acute therapies continue to dominate the market accounting for 70% of the market during the month
Chronic therapies registered growth of 15%, while acute therapies posted growth of 17% in Mar 15
Cough preparation was the highest selling therapeutic subgroup in value terms with significant growth of 30% during the
month
Source: IMS Health TSA, Mar 15
9
Top 40 brands
% Gwth
Augmentin (GlaxoSmithKline)
Top 1-10
Corex (Pfizer)
0.51
21
28
16
26
16
16
Foracort (Cipla)
16
Zifi (FDC)
15
23
38
0.31
23
36
0.31
23
Thyronorm (Abbott)
22
Clavam (Alkem)
21
20
20
18
25
8
29
% Gwth
20
19
Spasmo-Proxyvon + (Wockhardt)
19
Volini (Sun)
0.30
47
19
Novomix (Abbott)
19
Synflorix (GlaxoSmithKline)
18
18
0.29
37
0.22
40
0.21
20
0.21
37
0.21
15
13
0.20
Zincovit (Apex)
15
11
0.20
0.28
Calpol (GlaxoSmithKline)
15
27
0.20
Moxikind-CV (Mankind)
15
28
0.20
0.26
Pan (Alkem)
14
Value
(Rs. Crs)
Electral (FDC)
Duphaston (Abbott)
14
Taxim-O (Alkem)
14
0.24
0.24
0.19
Budecort (Cipla)
14
Azithral (Alembic)
13
Eltroxin (GlaxoSmithKline)
13
Zinetac (GlaxoSmithKline)
13
% MS
18
14
0.26
0.26
17
% Gwth
0.26
0.25
83
17
0.27
0.26
18
0.22
Becosules (Pfizer)
% MS
45
% MS
26
17
0.38
Prevenar-13 (Pfizer)
Glycomet-GP (U S V)
% Gwth
0.35
Value
(Rs. Crs)
Top 11-20
11
38
Top 21-30
Mixtard (Abbott)
Value
(Rs. Crs)
% MS
Top 31-40
Value
(Rs. Crs)
0.19
13
0.19
18
0.19
38
30
10
0.17
0.17
Lantus (Sanofi)
18
0.24
Taxim (Alkem)
13
14
0.17
18
0.24
13
13
0.17
17
0.23
Pan-D (Alkem)
12
20
25
Abbott, Alkem and GlaxoSmithKline have the highest number of brands among the top 40 at 5 each
The vaccine Synflorix (GlaxoSmithKline) registered outstanding growth of 83% during the month
Thyronorm (Abbott), Spasmo-Proxyvon + (Wockhardt) and Shelcal (Torrent Pharma) posted impressive growth
greater than 40% in Mar 15 over the same month last year
Source: IMS Health TSA, Mar 15
10
0.19
0.18
0.16
11
Therapy trends
Value (Rs Crs)
MS %
7,464
IPM
Cardiac
14
12
866
Gastro Intestinal
Pain / Analgesics
591
Anti Diabetic
589
535
Derma
456
Neuro / CNS
450
Gynaec.
416
Others
Vaccines
240
178
3
2
-4
13
-1
17
630
-1
20
10
774
Respiratory
16
100
1,066
Anti-infectives
Gwth % (SPLY)
21
-9
15
-1
18
11
17
-2
15
-1
11
22
36
12
16
54
48
44
Cefpodoxime Solids
42
Piperacillin+Tazobactam
33
Meropenem
33
30
Amikacin
29
39
27
30
22
7
16
Rabepra.+ Domperid.
43
27
GI
33
Atenolol+Amlodipine
32
Telmisartan + Hct
31
Enoxaparin
29
Amlodipine
29
38
15
47
23
20
22
12
15
11
6
9
26
24
18
% Gwth (SPLY)
35
176
67
42
Levocetiriz.+Montelu Sold
40
Formoteral+Budesonide
31
30
Salmeterol+Fluticasone
21
Omepraz.+ Domperid.
23
14
Budesonide
18
Rabeprazole
22
13
Salbutamol+Ipratropium
15
21
Levocetirizine
14
26
14
23
Value
(Rs. Crs)
24
14
29
24
Metoprolol
39
Others
40
25
47
Antacid+Antiflatu.Liq
Telmisartan
% Gwth (SPLY)
Pantopr.+ Domperid.
Pantoprazole Solids
43
Losartan+ Hydrochlorthiaz
% Gwth (SPLY)
66
Rosuvastatin
Amlodipine+Telmisartan
28
Value
(Rs. Crs)
Oral Electrolytes
Cardiac
Respiratory
Anti-Infective
30
57
Atorvastatin
28
95
Ceftriaxone Injectabls
Value
(Rs. Crs)
% Gwth (SPLY)
8
23
26
23
24
17
42
28
21
Oral Electrolytes, Budesonide, Amoxy. & Clav. Liquids and Cough Prep. Ethicals registered significant growth greater
than 34% over the same period last year
Source: IMS Health TSA, Mar 15
13
Glossary
Abbreviation
14
Description/Definition
IPM
MAT
CAGR
TSA
SSA
Gwth
Growth
MS
Market Share
Rs
Rupees
NLEM
SPLY
MNC
Multi-National Company
DPP
Dipeptidyl Peptidase 4
TC
Therapeutic Category
Crore / crs
10 million
95 process patents
worldwide in life sciences processes
PUBLIC HEALTH
PAYERS
PROVIDERS
Provider databases
Hospital performance transformation
programs
Performance benchmarking
Expansion & Growth strategy
Feasibility analysis and business plan
development
Brownfield hospital acquisition
Financial modeling, funding modalities
and transaction advisory
BI Solutions for hospitals
15
Disclaimer
16
The analyses, their interpretation, and related information contained herein are made and provided subject to the assumptions, methodologies, caveats,
and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the
completeness or accuracy of such third party sources or data.
IMS Health captures 90% of the retail sector and 65% of the hospital sector through individual audits, the Stockist Sell-Out Audit (SSA) and Hospital
Secondary Audit (HSA), as well as the dispensing doctors sector as part of the Total Sales Audit (TSA) from 2007 onwards. The combined audited
sectors accounted for an estimated 87.4% of the total pharmaceutical market in 2014.
As with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included herein are subject to certain risks
and uncertainties, and are not to be considered guarantees of any particular outcome.
It should neither be regarded as comprehensive nor sufficient for making decisions, nor should it be used in place of professional advice. IMS Health
accepts no responsibility for any loss arising from any action taken or not taken by anyone using this material.
All reproduction rights, quotations, broadcasting, publications reserved. No part of this presentation may be reproduced or transmitted in any form or by
any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without express written consent of
IMS HEALTH.
2015 IMS Health Incorporated and its affiliates. All rights reserved. Trademarks are registered in the United States and in various other countries.